Can varenicline help reduce falls in Parkinson disease?
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This phase 2 trial tests a medicine called varenicline (brand name Chantix) to see if it can reduce falls in people with Parkinson disease who also have a specific brain change (loss of a chemical called acetylcholine in the back of the brain) and mild cognitive problems. The study will help determine if this medicine is safe and effective for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Parkinson disease by a movement disorder specialist.
- You have mild cognitive impairment (some memory or thinking problems but not dementia) linked to Parkinson disease.
- You have a specific type of brain scan finding (low acetylcholine activity in the back of the brain) that will be checked by a special PET scan during screening.
- You are not currently using nicotine products (like cigarettes, e-cigarettes, or nicotine patches), anticholinergic drugs (like trihexyphenidyl or benztropine), or certain other medicines (your doctor will review).
- You can swallow pills and are willing to take study medication daily for the trial period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if pimavanserin can reduce impulse control disorders like gambling, shopping, hypersexuality, or overeating in people with Parkinson's disease. It aims to help those whose symptoms are moderate but not too severe.
This study tests whether playing virtual reality games can improve balance, reduce fall risk, and boost exercise ability in people with Parkinson's disease. You will attend therapy sessions that use a VR headset designed to help with movement.
This trial tests if adding vinpocetine to standard levodopa treatment can help Parkinson's disease patients. It aims to see if this combination improves symptoms.
This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.
This Phase 2 study tests whether an added medication strategy can change brain targets linked to memory decline in people with Parkinson’s disease, including those with no memory problems or mild memory changes. It may help lower risk of developing dementia, but you must be able to safely do MRI scans and meet other health and medication rules.
This study tests a treatment called Vibrotactile Coordinated Reset (VCR) to see if it can help people with early-stage Parkinson’s disease. It includes virtual check-ins and likely uses brain and finger sensation testing to monitor effects over time.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.